YPrime, a clinical technology provider known for its electronic Clinical Outcome Assessment (eCOA), Interactive Response Technology (IRT), and eConsent platforms, received the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials in the 2025 Clinical Trials Arena Excellence Awards.
The company was recognized for addressing a high-friction workflow with domain-specific AI while embedding sustainability into product design, operations, and supplier management.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Clinical Trials Arena Excellence Awards honor the most significant achievements and innovations in the pharmaceutical clinical trials industry. Powered by GlobalData’s business intelligence, the Awards recognize the people and companies leading positive change and shaping the future of the industry.
AI in eCOA localization: Faster activations, cleaner data, lower risk
YPrime’s innovation targets a persistent bottleneck that rarely draws attention: the migration of paper Clinical Outcome Assessment (COA) translations into eCOA software. Paper instruments and eCOA structures differ in layout, tags, and response formats, so direct substitution of language strings is not enough. Historically, teams relied on manual adjustments and multiple rounds of proofreading to resolve issues such as HTML tagging conflicts, field mapping inconsistencies, and subtle linguistic nuances. This approach is slow, error-prone, and costly—and delays regulatory approvals and site activations.
The company reframed the problem by automating the migration step itself. Its AI system is trained on YPrime’s own eCOA file structures and technical syntax, augmented by linguistic datasets that account for formatting and grammar variations across languages. By narrowing the scope to a single technical environment rather than accommodating multiple vendors’ formats, the tool achieves deeper optimization and consistent accuracy. In practice, it performs the heavy lifting that previously required expert manual intervention—mapping fields, aligning tags, validating response options, and flagging anomalies for targeted human review—reducing cognitive burden on reviewers and limiting downstream rework.
The performance data is specific. In a comparative analysis of 15 projects, the AI tool reduced migration errors by 74% and cut the number of reports requiring rework by 60%. Those gains matter because they move endpoints that sponsors track closely: screen-report approvals, regulatory submission readiness, and site activation dates.
A case in point involved the late addition of India to an ongoing study. Onboarding a new country typically takes nine weeks, especially when Indic languages and formatting constraints are involved. With the AI-enabled migration approach, YPrime completed the work in three weeks with minimal disruption to the live study—compressing timelines without sacrificing linguistic accuracy or data integrity. According to YPrime, this is the first known application of AI to localization migration workflows in eCOA, and it addresses a root-cause problem rather than treating symptoms through more proofreading. The result is a repeatable path to earlier approvals, faster activations, and cleaner datasets at scale.
“Our eCOA localization capabilities are a significant leap in clinical trial efficiency. By accelerating eCOA localization with modern approaches to key parts of the process such as migration, we empower sponsors to reach a broader, more diverse patient population while adhering to stringent timelines. Our unique approach drives the collection of high-quality, representative data on an international scale. Ultimately, our goal is to support patient access to trials, wherever they are in the world, and remove associated operational barriers for trial sponsors, leading to better health outcomes across diverse global populations.”
– Jonathan Norman, Director of Localization & Scale Management at YPrime
Sustainable trials by design: Circularity, verified ESG progress, and supplier accountability
YPrime integrates sustainability into how trials are designed and run, not just into back-office operations. The company’s digital-first platforms—eConsent, eCOA, and IRT—replace paper-based processes and reduce the need for shipping and site visits, which are major contributors to Scope 3 emissions in clinical research. Capabilities that enable decentralized and hybrid models—such as remote data capture, real-time ePRO syncing to sponsor dashboards, and device integrations—further limit travel and physical materials. Over multiple years, this has translated into sustained reductions in printed trial documents and internal paper use, with more than 90% of trial documentation now delivered digitally and a reported 87% reduction in printed trial documents across three years.
Operational measures back up the product-level choices. In 2024, YPrime established a full Scope 1, 2, and 3 emissions baseline, consolidated U.S. office space to reduce electricity consumption, and focused on energy efficiency across cloud and facilities. Circularity is operationalized through 100% reuse or recycling of used hardware, supported by responsible refurbishment and donation partnerships that extend device life and reduce e-waste. Logistics teams have introduced recyclable or minimal packaging and shipment consolidation, with a pilot for logistics-related emissions tracking planned with partners—steps that directly target emissions tied to freight and purchased goods.
Governance and external validation strengthen credibility. ESG criteria are embedded into request for proposals (RFPs), Tier 1 suppliers receive a Supplier Code of Conduct, and due diligence processes are in place to monitor environmental and social risks. In 2024, the company earned an EcoVadis bronze medal placing in the 73rd percentile of all organizations assessed and achieved a CDP “B” rating, reflecting maturing environmental management and disclosure. The firm is a proud member of the UN Global Compact and formally committed to near-term science-based targets, signaling an intent to measure and manage impact across the value chain. Together, the digital-first product design, full emissions baselining, circular practices, and supplier accountability demonstrate meaningful decarbonization and resource efficiency embedded in the clinical trial workflow.
“At YPrime, we believe that doing good and doing well are not opposing ideas, they are mutually reinforcing commitments. As a company at the forefront of clinical technology, we are proud of the role we play in advancing global health by accelerating drug development and improving access to life-changing clinical trials. We’ve embedded ethical governance, human-centered values, and environmental responsibility into our core business strategy—from reducing our environmental footprint and strengthening supplier oversight, to supporting our employees and improving access to clinical research for underrepresented communities. Our actions reflect a clear direction: to lead responsibly and inclusively.”
– Ian Lennox, CEO, YPrime
Company Profile
YPrime simplifies global clinical trials with eCOA, IRT, and eConsent solutions that combine speed, flexibility, and quality. The YPrime eCOA platform enhances participant compliance through an intuitive app and streamlined site workflows, integrates seamlessly with connected devices, and equips sponsors with real-time dashboards for confident decision-making. Its AI-powered localization and migration engine accelerates study startup by improving translation workflows—delivering faster, more accurate multilingual eCOA deployments that enable data integrity and broader global participation. Pre-validated and configurable eCOA and IRT solutions deliver rapid startup and consistently high quality across all phases of clinical research.
Beyond industry-leading eClinical solutions, YPrime is advancing the future of sustainable clinical research. The company’s platforms are designed to reduce environmental impact through paper-free data capture, optimized logistics, and circular device reuse and recycling programs. YPrime has already achieved zero direct (Scope 1) greenhouse gas emissions and is actively reducing indirect (Scope 2 and 3) emissions.
Trusted by top pharmaceutical leaders and emerging biotech innovators alike, YPrime combines deep industry expertise with cutting-edge technology to deliver reliable, scalable solutions. With nearly two decades of experience, solutions in more than 250 languages, and operations in more than 100 countries, YPrime is your partner in solving clinical research challenges with speed, precision, and certainty.
Links
Website: www.yprime.com
Learn more about eCOA: www.yprime.com/ecoa
Learn more about YPrime Advanced eCOA Localization: https://www.yprime.com/yprime-announces-advanced-ecoa-localization-capabilities/
YPrime ESG Report: www.yprime.com/esg-report-2024
